The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1174
January 19, 2004
View Complete Issue         Table of Contents 2019 
Zolmitriptan (Zomig) Nasal Spray for Migraine
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Zolmitriptan (Zomig) Nasal Spray for Migraine
January 19, 2004 (Issue: 1174)
Zolmitriptan (Zomig - AstraZeneca) nasal spray was recently approved by the FDA for treatment of migraine. It is the second selective serotonin receptor agonist ("triptan") to become available as a nasal spray; sumatriptan has been available in this...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Zolmitriptan (Zomig) Nasal Spray for Migraine
Article code: 1174b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.